Medication Guide App

Coagulation Factor Ix Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Factor IX Deficiency

Dosage and duration of treatment for all factor IX products depend on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition, age and recovery of factor IX.

In general, one IU of coagulation factor IX per kilogram of body weight increased the circulating activity of factor IX as follows: 0.8 + or - 0.2 IU/dL [range 0.4 to 1.2 IU/dL].

One international unit of Rixubis per kg of body weight increased the circulating activity of factor IX by 0.9 international units/dL.

The following formula may be used as a guide in determining the dose for treatment of bleeding episodes:
Initial dose (number of factor IX IU required) = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg)

Control and Prevention of Bleeding Episodes and Perioperative Management:
Minor
Uncomplicated hemarthroses, superficial muscle, or soft tissue:
Circulating Factor IX Activity Required: 20-30 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 1 to 2 days

Moderate
Intramuscular or soft tissue with dissection, mucous membranes, dental extractions, or hematuria:
Circulating Factor IX Activity Required: 25 to 50 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: Treat until bleeding stops and healing begins, about 2 to 7 days

Major
Pharynx, retropharynx, retroperitoneum, CNS, surgery:
Circulating Factor IX Activity Required: 50 to 100 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 7 to 10 days

Rixubis dosing for Perioperative Management:
Minor
Tooth extraction:
Circulating Factor IX Activity Required: 30 to 60 [% or (IU/dL)]
Dosing Interval: 24 hours
Duration of Therapy: At least 1 day, until healing is achieved

Major
Intracranial, intraabdominal, intrathoracic, joint replacement:
Circulating Factor IX Activity Required: 80 to 100 [% or (IU/dL)]
Dosing Interval: 8 to 24 hours
Duration of Therapy: 7 to 10 days

Rixubis Routine Prophylaxis dose: 40 to 60 international units per kg IV twice weekly

Usual Adult Dose for Hemophilia B

Dosage and duration of treatment for all factor IX products depend on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition, age and recovery of factor IX.

In general, one IU of coagulation factor IX per kilogram of body weight increased the circulating activity of factor IX as follows: 0.8 + or - 0.2 IU/dL [range 0.4 to 1.2 IU/dL].

One international unit of Rixubis per kg of body weight increased the circulating activity of factor IX by 0.9 international units/dL.

The following formula may be used as a guide in determining the dose for treatment of bleeding episodes:
Initial dose (number of factor IX IU required) = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg)

Control and Prevention of Bleeding Episodes and Perioperative Management:
Minor
Uncomplicated hemarthroses, superficial muscle, or soft tissue:
Circulating Factor IX Activity Required: 20-30 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 1 to 2 days

Moderate
Intramuscular or soft tissue with dissection, mucous membranes, dental extractions, or hematuria:
Circulating Factor IX Activity Required: 25 to 50 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: Treat until bleeding stops and healing begins, about 2 to 7 days

Major
Pharynx, retropharynx, retroperitoneum, CNS, surgery:
Circulating Factor IX Activity Required: 50 to 100 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 7 to 10 days

Rixubis dosing for Perioperative Management:
Minor
Tooth extraction:
Circulating Factor IX Activity Required: 30 to 60 [% or (IU/dL)]
Dosing Interval: 24 hours
Duration of Therapy: At least 1 day, until healing is achieved

Major
Intracranial, intraabdominal, intrathoracic, joint replacement:
Circulating Factor IX Activity Required: 80 to 100 [% or (IU/dL)]
Dosing Interval: 8 to 24 hours
Duration of Therapy: 7 to 10 days

Rixubis Routine Prophylaxis dose: 40 to 60 international units per kg IV twice weekly

Usual Pediatric Dose for Factor IX Deficiency

Dosage and duration of treatment for all factor IX products depend on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition, age and recovery of factor IX.

In general, one IU of coagulation factor IX per kilogram of body weight increased the circulating activity of factor IX as follows: 0.7 + or - 0.3 IU/dL [range 0.2 to 2.1 IU/dL].

The following formula may be used as a guide in determining the dose for treatment of bleeding episodes:
Initial dose (number of factor IX IU required) = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg)

Minor
Uncomplicated hemarthroses, superficial muscle, or soft tissue:
Circulating Factor IX Activity Required: 20-30 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 1 to 2 days

Moderate
Intramuscular or soft tissue with dissection, mucous membranes, dental extractions, or hematuria:
Circulating Factor IX Activity Required: 25 to 50 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: Treat until bleeding stops and healing begins, about 2 to 7 days

Major
Pharynx, retropharynx, retroperitoneum, CNS, surgery:
Circulating Factor IX Activity Required: 50 to 100 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 7 to 10 days

Safety and efficacy of Rixubis in pediatric patients have not been established.

Usual Pediatric Dose for Hemophilia B

Dosage and duration of treatment for all factor IX products depend on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition, age and recovery of factor IX.

In general, one IU of coagulation factor IX per kilogram of body weight increased the circulating activity of factor IX as follows: 0.7 + or - 0.3 IU/dL [range 0.2 to 2.1 IU/dL].

The following formula may be used as a guide in determining the dose for treatment of bleeding episodes:
Initial dose (number of factor IX IU required) = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg)

Minor
Uncomplicated hemarthroses, superficial muscle, or soft tissue:
Circulating Factor IX Activity Required: 20-30 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 1 to 2 days

Moderate
Intramuscular or soft tissue with dissection, mucous membranes, dental extractions, or hematuria:
Circulating Factor IX Activity Required: 25 to 50 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: Treat until bleeding stops and healing begins, about 2 to 7 days

Major
Pharynx, retropharynx, retroperitoneum, CNS, surgery:
Circulating Factor IX Activity Required: 50 to 100 [% or (IU/dL)]
Dosing Interval: 12 to 24 hours
Duration of Therapy: 7 to 10 days

Safety and efficacy of Rixubis in pediatric patients have not been established.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dialysis

Data not available

Hide
(web5)